Loading...
XNAS
QLGN
Market cap2mUSD
Jul 14, Last price  
3.69USD
1D
7.89%
1Q
11.82%
Jan 2017
-99.95%
IPO
-99.97%
Name

Qualigen Therapeutics Inc

Chart & Performance

D1W1MN
No data to show
P/E
P/S
0.52
EPS
Div Yield, %
Shrs. gr., 5y
57.08%
Rev. gr., 5y
-2.15%
Revenues
5m
+4.44%
0009,775,6405,803,0445,557,9674,306,3165,653,7254,983,5565,204,755
Net income
-13m
L-36.21%
-2,473,465-9,178,623-18,384,634-7,863,858-1,200,366-1,787,512-20,418,942-17,897,137-21,034,643-13,417,212
CFO
-10m
L-22.22%
-1,157,385-5,721,565-15,208,718-7,397,912-13,332,92757,331-9,755,221-14,730,742-13,247,540-10,304,263

Profile

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
IPO date
Jun 24, 2015
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122020‑032018‑122017‑122016‑122015‑12
Income
Revenues
5,205
4.44%
4,984
-11.85%
Cost of revenue
16,510
22,926
Unusual Expense (Income)
NOPBT
(11,305)
(17,942)
NOPBT Margin
Operating Taxes
(5)
(265)
Tax Rate
NOPAT
(11,300)
(17,677)
Net income
(13,417)
-36.21%
(21,035)
17.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
7
BB yield
-0.13%
Debt
Debt current
1,299
1,406
Long-term debt
2,999
Deferred revenue
49
Other long-term liabilities
Net debt
897
(2,635)
Cash flow
Cash from operating activities
(10,304)
(13,248)
CAPEX
(319)
Cash from investing activities
4,216
(184)
Cash from financing activities
(550)
2,911
FCF
(7,862)
(17,595)
Balance
Cash
402
7,034
Long term investments
6
Excess cash
142
6,791
Stockholders' equity
(116,759)
(101,761)
Invested Capital
115,955
113,253
ROIC
ROCE
1,405.48%
EV
Common stock shares outstanding
5,073
3,840
Price
0.55
-57.33%
1.29
-87.95%
Market cap
2,790
-43.64%
4,950
-84.23%
EV
3,687
3,846
EBITDA
(11,300)
(17,567)
EV/EBITDA
Interest
1,525
27
Interest/NOPBT